20 Ameratunga NZMJ ACE2 decoy.pdf (501.9 kB)
Download file

Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection

Download (501.9 kB)
journal contribution
posted on 04.08.2022, 22:21 authored by R Ameratunga, K Lehnert, E Leung, Davide ComolettiDavide Comoletti, R Snell, ST Woon, W Abbott, E Mears, R Steele, J McKee, A Muscroff-Taylor, S Ameratunga, N Medlicott, S Das, W Rolleston, ME Quinones-Mateu, H Petousis-Harris, A Jordan
COVID-19 is a new zoonotic disease caused by the SARS-CoV-2 virus. Since its emergence in Wuhan City, China, the virus has rapidly spread across the globe causing calamitous health, economic and societal consequences. It causes disproportionately severe disease in the elderly and those with co-morbidities, such as hypertension and diabetes. There is currently no proven treatment for COVID-19 and a safe and effective vaccine is at least a year away. The virus gains access to the respiratory epithelium through cell surface angiotensin converting enzyme 2 (ACE2). The receptor binding domain (RBD) of the virus is unlikely to mutate without loss of pathogenicity and thus represents an attractive target for antiviral treatment. Inhaled modified recombinant human ACE2, may bind SARS-CoV-2 and mitigate lung damage. This decoy strategy is unlikely to provoke an adverse immune response and may reduce morbidity and mortality in high-risk groups.

History

Preferred citation

Ameratunga, R., Lehnert, K., Leung, E., Comoletti, D., Snell, R., Woon, S. T., Abbott, W., Mears, E., Steele, R., McKee, J., Muscroff-Taylor, A., Ameratunga, S., Medlicott, N., Das, S., Rolleston, W., Quinones-Mateu, M. E., Petousis-Harris, H. & Jordan, A. (2020). Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. New Zealand Medical Journal, 133(1515), 112-118. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592128200012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=fce46881ccd595a90ef171eda32e42ef

Journal title

New Zealand Medical Journal

Volume

133

Issue

1515

Publication date

22/05/2020

Pagination

112-118

Publication status

Published

ISSN

0028-8446

eISSN

1175-8716

Language

en